This study will recruit a total of 40 evaluable subjects (20 cognitively depressive, and 20 AD depressive); each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping.
Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events.
This study is expected to be completed in a period of 3 years.

Start Date01 May 2010

Sponsor / Collaborator

Chang Gung Memorial Hospital

100 Clinical Results associated with I-123 ADAM

100 Translational Medicine associated with I-123 ADAM

100 Patents (Medical) associated with I-123 ADAM

Literatures (Medical) associated with I-123 ADAM

01 Aug 2010·Nuclear Medicine CommunicationsQ4 · MEDICINE

New methods for registering long-time I-123 ADAM SPECT image sequences to magnetic resonance images

Q4 · MEDICINE

Article

Author: Chung I. Huang ; Yung Nien Sun ; Wei Jen Yao

BACKGROUNDI-123 ADAM single-photon emission tomography (SPECT) analysis is usually performed by drawing regions of interest or by directly registering the SPECT image to a magnetic resonance image (MRI). Each method is limited by an observer or registration bias.METHODSEleven healthy volunteers were recruited for I-123 ADAM SPECT using a triple-headed gamma camera with fan-beam collimators after an intravenous injection of 185 MBq of I-123 ADAM. We propose two new registration methods: sequential registration and a two-step registration. Reconstructed images were registered to MRIs using mutual information with sequential and two-step methods.RESULTSThe sequential and two-step method mean counts of midbrain activity were not significantly different (166.1+/-4.3 vs. 164.2+/-4.1, P=0.273), but they were significantly higher than the direct method mean count (132.8+/-3.7, P<0.001). Sequential and two-step method midbrain/cerebellum ratios were not significantly different (4.40+/-0.37 vs. 4.28+/-0.34, P=0.277), but they were significantly higher than the direct method midbrain/cerebellum ratio (1.68+/-0.16, P<0.001).CONCLUSIONThe accuracy of the sequential method of registration was significantly better than that of drawing regions of interest or directly coregistering the SPECT image to an MRI. It is, however, tedious and time-consuming. The simplified two-step method yields similar results and is more practical for clinical I-123 ADAM SPECT studies.

100 Deals associated with I-123 ADAM

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Anxiety Disorders	Phase 2	-	Tri-Service General Hospital	31 Oct 2011
Alzheimer Disease, Familial, Type 3	Phase 2	-	Chang Gung Memorial Hospital	31 May 2010
Behavioural disorders	Phase 2	-	Chang Gung Memorial Hospital	31 May 2010
Depressive Disorder	Phase 2	-	Chang Gung Memorial Hospital	01 May 2010

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

I-123 ADAM

Overview

Basic Info

Structure

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation